Combination Therapy of Multiple Micro Trauma Technology on Hepatocellular Carcinoma

Objective: To compare efficacy of therapy scheme as Transhepatic Artery Chemoembolization (TACE) + Radiofrequency Ablation (RFA) + Introportal Vein Chemotherapy (PVC) + Percutaneous Ethanol Injection (PEI) therapy (quadruplet group) with TACE + RFA combinational therapy (diad group) in treating hepatocellular carcinoma (HCC). Methods: 25 cases in quadruplet group were treated by TACE for 3 weeks, then by RFA, after 2 months, by PVC + PEI; 23 cases in diad group were treated by TACE for 3 weeks and then by PEI. After completion of each treatment course in both groups, Alphafetoprotein (AFP) was tested 2 months later; abdomen colorful doppler, CT and AFP were retested 6 months later. Results: AFP was significantly decreased in 23 cases of quadruplet group and 20 cases of diad group among those with AFP positive results. 6 months later, examinations of CT, colorful Doppler and AFP in two groups showed: quadruplet group has significantly decreased (X2 = 6.81, P 0.01) blood supply of cancer tissue and significantly diminished (X2 = 8.29, P 0.01) tumor size, few cases with AFP elevation (X2 = 5.06, P 0.05); lower 1 year relapse rate and two years mortality than that in diad group (X2 = 5.30, P 0.05). Conclusion: TACE + RFA + PVC + PEI combinational therapy is a safe double intervention treatment for HCC scheme with less side effects, which is better than TACE + PEI scheme in killing remnant tumor and reducing relapse.

[1]  Wei Yang,et al.  Efficacy and feasibility of radiofrequency ablation for decompensated cirrhotic patients with hepatocellular carcinoma. , 2010, Chinese medical journal.

[2]  G. Cabibbo,et al.  Multimodal approaches to the treatment of hepatocellular carcinoma , 2009, Nature Clinical Practice Gastroenterology &Hepatology.

[3]  J. Bruix,et al.  Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.

[4]  X. Xiaoyan.  Use of percutaneous thermal ablation for treatment of reoperable recurrent hepatocellular carcinoma after liver resection , 2006 .

[5]  Xu Huixiong.  Ultrasound-guided percutaneous thermal ablation for treatment of hepatocellular carcinoma , 2005 .

[6]  H-X Xu,et al.  Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation. , 2004, Clinical radiology.

[7]  J. H. Lim,et al.  Recurrent hepatocellular carcinoma: percutaneous radiofrequency ablation after hepatectomy. , 2004, Radiology.

[8]  Li Mei-rong.  Combined superselective transcatheter arterial chemoembolization and selective intraportal venous embolization for the treatment of inoperable advanced primary liver cancer , 2004 .

[9]  Wang Gaoxiong.  TACE in combination with RF in treatment of advanced HCC , 2003 .

[10]  D. Xi.  Transcatheter hepatic artery embolization helps radiofrequency ablation of hepatic neoplasms , 2000 .

[11]  H. Taniguchi,et al.  Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling , 1993, Cancer.